Berdazimer sodium, sold under the brand name Zelsuvmi, is a medication used for the treatment for molluscum contagiosum.[1] Berdazimer sodium is a nitric oxide releasing agent.[1] It is a polymer formed from sodium 1-hydroxy-3-methyl-3-(3-(trimethoxysilyl)propyl)-1-triazene-2-oxide and tetraethyl silicate.[2]
^ abcdefghi"Zelsuvmi (berdazimer) topical gel" (PDF). (PDF) from the original on 19 January 2024. Retrieved 9 January 2024.
^"GSRS". gsrs.ncats.nih.gov. from the original on 8 January 2024. Retrieved 8 January 2024.
^"Drug Approval Package: Zelsuvmi". U.S. Food and Drug Administration (FDA). 2 February 2024. from the original on 11 March 2024. Retrieved 11 March 2024.
^ ab"Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 29 April 2024. from the original on 30 April 2024. Retrieved 30 April 2024.
^"U.S. Food and Drug Administration Approves Zelsuvmi as a First-in-Class Medication for the Treatment of Molluscum Contagiosum". Ligand Pharmaceuticals. 5 January 2024. from the original on 8 January 2024. Retrieved 8 January 2024 – via Business Wire.
^World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.
Further readingedit
Pera Calvi I, R Marques I, Cruz SA, Mesquita YL, Padrao EM, Souza RM, et al. (2023). "Safety and efficacy of topical nitric oxide-releasing berdazimer gel for molluscum contagiosum clearance: A systematic review and meta-analysis of randomized controlled trials". Pediatric Dermatology. 40 (6): 1060–1063. doi:10.1111/pde.15419. PMID 37721050. S2CID 262045499.
Han H, Smythe C, Yousefian F, Berman B (February 2023). "Molluscum Contagiosum Virus Evasion of Immune Surveillance: A Review". Journal of Drugs in Dermatology. 22 (2): 182–189. doi:10.36849/JDD.7230. PMID 36745361. S2CID 256613906.
Lacarrubba F, Micali G, Trecarichi AC, Quattrocchi E, Monfrecola G, Verzì AE (December 2022). "New Developing Treatments for Molluscum Contagiosum". Dermatology and Therapy. 12 (12): 2669–2678. doi:10.1007/s13555-022-00826-7. PMC9674806. PMID 36239905.
Ward BM, Riccio DA, Cartwright M, Maeda-Chubachi T (November 2023). "The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology". Viruses. 15 (12): 2360. doi:10.3390/v15122360. PMC10747301. PMID 38140601.
Clinical trial number NCT04535531 for "A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (B-SIMPLE4)" at ClinicalTrials.gov
Clinical trial number NCT03927703 for "A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC (B-SIMPLE2)" at ClinicalTrials.gov
Clinical trial number NCT03927716 for "A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)" at ClinicalTrials.gov
berdazimer, sodium, sold, under, brand, name, zelsuvmi, medication, used, treatment, molluscum, contagiosum, nitric, oxide, releasing, agent, polymer, formed, from, sodium, hydroxy, methyl, trimethoxysilyl, propyl, triazene, oxide, tetraethyl, silicate, clinic. Berdazimer sodium sold under the brand name Zelsuvmi is a medication used for the treatment for molluscum contagiosum 1 Berdazimer sodium is a nitric oxide releasing agent 1 It is a polymer formed from sodium 1 hydroxy 3 methyl 3 3 trimethoxysilyl propyl 1 triazene 2 oxide and tetraethyl silicate 2 Berdazimer sodiumClinical dataTrade namesZelsuvmiOther namesSB206License dataUS DailyMed Berdazimer sodiumRoutes ofadministrationTopicalATC codeNoneLegal statusLegal statusUS only 1 IdentifiersCAS Number1846565 00 1DrugBankDBSALT003491DB18712UNIIORT9SID4QYB23P7SM943KEGGD12758ChEMBLChEMBL4298064Chemical and physical dataFormulaIndeterminate 1 Molar massIndeterminate 1 Berdazimer sodium was approved for medical use in the United States in January 2024 3 4 5 Contents 1 Medical uses 2 Pharmacology 2 1 Mechanism of action 2 2 Pharmacodynamics 3 Society and culture 3 1 Legal status 3 2 Names 4 References 5 Further reading 6 External linksMedical uses editBerdazimer sodium is indicated for the topical treatment of molluscum contagiosum 1 Pharmacology editMechanism of action edit Berdazimer sodium is a nitric oxide releasing agent 1 The mechanism of action for the treatment of molluscum contagiosum is unknown 1 Pharmacodynamics edit The pharmacodynamics of berdazimer sodium are unknown 1 Society and culture editLegal status edit Berdazimer sodium was approved for medical use in the United States in January 2024 4 Names edit Berdazimer sodium is the international nonproprietary name 6 References edit a b c d e f g h i Zelsuvmi berdazimer topical gel PDF Archived PDF from the original on 19 January 2024 Retrieved 9 January 2024 GSRS gsrs ncats nih gov Archived from the original on 8 January 2024 Retrieved 8 January 2024 Drug Approval Package Zelsuvmi U S Food and Drug Administration FDA 2 February 2024 Archived from the original on 11 March 2024 Retrieved 11 March 2024 a b Novel Drug Approvals for 2024 U S Food and Drug Administration FDA 29 April 2024 Archived from the original on 30 April 2024 Retrieved 30 April 2024 U S Food and Drug Administration Approves Zelsuvmi as a First in Class Medication for the Treatment of Molluscum Contagiosum Ligand Pharmaceuticals 5 January 2024 Archived from the original on 8 January 2024 Retrieved 8 January 2024 via Business Wire World Health Organization 2018 International nonproprietary names for pharmaceutical substances INN recommended INN list 79 WHO Drug Information 32 1 hdl 10665 330941 Further reading editPera Calvi I R Marques I Cruz SA Mesquita YL Padrao EM Souza RM et al 2023 Safety and efficacy of topical nitric oxide releasing berdazimer gel for molluscum contagiosum clearance A systematic review and meta analysis of randomized controlled trials Pediatric Dermatology 40 6 1060 1063 doi 10 1111 pde 15419 PMID 37721050 S2CID 262045499 Han H Smythe C Yousefian F Berman B February 2023 Molluscum Contagiosum Virus Evasion of Immune Surveillance A Review Journal of Drugs in Dermatology 22 2 182 189 doi 10 36849 JDD 7230 PMID 36745361 S2CID 256613906 Lacarrubba F Micali G Trecarichi AC Quattrocchi E Monfrecola G Verzi AE December 2022 New Developing Treatments for Molluscum Contagiosum Dermatology and Therapy 12 12 2669 2678 doi 10 1007 s13555 022 00826 7 PMC 9674806 PMID 36239905 Ward BM Riccio DA Cartwright M Maeda Chubachi T November 2023 The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology Viruses 15 12 2360 doi 10 3390 v15122360 PMC 10747301 PMID 38140601 External links edit Berdazimer Sodium Code C174810 NCI Thesaurus Clinical trial number NCT04535531 for A Phase 3 Molluscum Contagiosum Efficacy and Safety Study B SIMPLE4 at ClinicalTrials gov Clinical trial number NCT03927703 for A Phase 3 Efficacy amp Safety of SB206 amp Vehicle Gel for the Treatment of MC B SIMPLE2 at ClinicalTrials gov Clinical trial number NCT03927716 for A Phase 3 Randomized Parallel Group Study Comparing the Efficacy amp Safety of SB206 amp Vehicle Gel in the Treatment of MC B SIMPLE1 at ClinicalTrials gov Portals nbsp Medicine nbsp Viruses Retrieved from https en wikipedia org w index php title Berdazimer sodium amp oldid 1221475703, wikipedia, wiki, book, books, library,
